ESCI

Wolters Kluwer delivers strong Lippincott journal performance in 2023 Journal Citation Reports

Retrieved on: 
Wednesday, August 9, 2023
Science, Software, Research, Publishing, General Health, Health, Communications, Technology, Learning, Sports medicine, Journal Citation Reports, Obstetrics, Circulation, Anesthesiology, American College of Sports Medicine, Hearing, ESCI, COVID-19, Jif, Wolters Kluwer, Testosterone and the cardiovascular system, Multimedia, Doctor of Philosophy, Impact factor, Wolters, Student, Patient, Transplant, Gynaecology, Clarivate, American College, Ear, Peripheral artery disease, JCR, Emerging Sources Citation Index, Lippincott, Pharmaceutical industry, Video game

Wolters Kluwer Health today announced strong results for the Lippincott portfolio of journals in the 2022 Journal Impact Factor (JIF), the journal metric released annually by Clarivate Analytics as part of the Journal Citation Reports (JCR).

Key Points: 
  • Wolters Kluwer Health today announced strong results for the Lippincott portfolio of journals in the 2022 Journal Impact Factor (JIF), the journal metric released annually by Clarivate Analytics as part of the Journal Citation Reports (JCR).
  • The 2023 rankings featured 387 Wolters Kluwer journals, with more than half (52%) receiving improved rankings from the previous year and an overall net increase for the portfolio.
  • To learn more about the titles within the Wolters Kluwer Lippincott publishing lineup, please visit lww.com .
  • The division of Wolters Kluwer supports clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions.

Clarivate Unveils Journal Citation Reports 2023 - a Trusted Resource to Support Research Integrity and Promote Accurate Journal Evaluation

Retrieved on: 
Wednesday, June 28, 2023
Maintenance, Clarivate, Social, Journal Citation Reports, Web of Science, The arts, Senior, CLVT, Emerging Sources Citation Index, ESCI, Intelligence, Arts and Humanities Citation Index, Research, Impact factor, Science, Organization, Humanities, AHCI, NYSE, JCR, Pharmaceutical industry

LONDON, June 28, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released the 2023 update to its annual Journal Citation Reports™ (JCR)™. This annual release identifies more than 21,500 high-quality academic journals from across 250+ scientific and research disciplines. Only journals that have met the rigorous quality standards for inclusion in the Web of Science™ index are selected, to ensure that users can confidently rely on the information and data provided to foster and support collective community goals to adhere to research integrity norms.

Key Points: 
  • This annual release identifies more than 21,500 high-quality academic journals from across 250+ scientific and research disciplines.
  • For nearly half a century, the information released in the annual Journal Citation Reports has been trusted by the global academic community as a reliable resource for identifying leading journals in their fields.
  • It provides clarity of key citation impact trends, powered by a range of indicators, descriptive data and compelling visualizations, enabling meaningful comparisons and insights.
  • The annual reports incorporate a variety of metrics, including the widely recognized Journal Impact Factor™ (JIF)™ and the Journal Citation Indicator.

Clarivate Unveils Journal Citation Reports 2023 - a Trusted Resource to Support Research Integrity and Promote Accurate Journal Evaluation

Retrieved on: 
Wednesday, June 28, 2023
Maintenance, Clarivate, Social, Journal Citation Reports, Web of Science, The arts, Senior, CLVT, Emerging Sources Citation Index, ESCI, Intelligence, Arts and Humanities Citation Index, Research, Impact factor, Science, Organization, Humanities, AHCI, NYSE, JCR, Pharmaceutical industry

LONDON, June 28, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today released the 2023 update to its annual Journal Citation Reports™ (JCR)™. This annual release identifies more than 21,500 high-quality academic journals from across 250+ scientific and research disciplines. Only journals that have met the rigorous quality standards for inclusion in the Web of Science™ index are selected, to ensure that users can confidently rely on the information and data provided to foster and support collective community goals to adhere to research integrity norms.

Key Points: 
  • This annual release identifies more than 21,500 high-quality academic journals from across 250+ scientific and research disciplines.
  • For nearly half a century, the information released in the annual Journal Citation Reports has been trusted by the global academic community as a reliable resource for identifying leading journals in their fields.
  • It provides clarity of key citation impact trends, powered by a range of indicators, descriptive data and compelling visualizations, enabling meaningful comparisons and insights.
  • The annual reports incorporate a variety of metrics, including the widely recognized Journal Impact Factor™ (JIF)™ and the Journal Citation Indicator.

Clarivate announces changes to the 2023 Journal Citation Reports All Web of Science Core Collection journals, including arts and humanities will have Journal Impact Factors

Retrieved on: 
Tuesday, July 26, 2022
Social Sciences Citation Index, Western literature, Improper integral, Editorial, AHCI, Professional services, Global South, Gold, Technology, Policy, Review, Ecosystem, Librarian, Journal Citation Reports, Institute for Scientific Information, Science Citation Index, CVS, Impact factor, Research, Solution, Clarivate, Arts and Humanities Citation Index, JCR, JIF, Metric, Emerging Sources Citation Index, Web of Science, List of life sciences, Health care, ISI, Twitter, Final good, Institute, Academy, Publication, The arts, Humanities, ESCI, EU, SSCI, Center, Factor X, International Society for Scientometrics and Informetrics, NYSE, CWTS, Behavior, SCIE, Leiden University, Invention, Science and Technology Select Committee, Pharmaceutical industry, Periodical literature, Publishing, Book, Medical device, Management, Science

This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).

Key Points: 
  • This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).
  • I welcome the expansion of the JIF to all journals in Web of Science Core Collection.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.
  • You can find more information including our suppression policy in the Journal Citation Reports Reference Guide .

Clarivate announces changes to the 2023 Journal Citation Reports All Web of Science Core Collection journals, including arts and humanities will have Journal Impact Factors

Retrieved on: 
Tuesday, July 26, 2022
Social Sciences Citation Index, Western literature, Improper integral, Editorial, AHCI, Professional services, Global South, Gold, Technology, Policy, Review, Ecosystem, Librarian, Journal Citation Reports, Institute for Scientific Information, Science Citation Index, CVS, Impact factor, Research, Solution, Clarivate, Arts and Humanities Citation Index, JCR, JIF, Metric, Emerging Sources Citation Index, Web of Science, List of life sciences, Health care, ISI, Twitter, Final good, Institute, Academy, Publication, The arts, Humanities, ESCI, EU, SSCI, Center, Factor X, International Society for Scientometrics and Informetrics, NYSE, CWTS, Behavior, SCIE, Leiden University, Invention, Science and Technology Select Committee, Pharmaceutical industry, Periodical literature, Publishing, Book, Medical device, Management, Science

This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).

Key Points: 
  • This means expanding the JIF from Science Citation Index Expanded (SCIE) and Social Science Citation Index (SSCI) to include journals from the Arts and Humanities Citation Index (AHCI)and the multidisciplinary Emerging Sources Citation Index (ESCI).
  • I welcome the expansion of the JIF to all journals in Web of Science Core Collection.
  • These include:
    The Journal Citation Indicator, which represents the average category-normalized citation impact for papers published in the prior three-year period.
  • You can find more information including our suppression policy in the Journal Citation Reports Reference Guide .

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

Retrieved on: 
Thursday, November 18, 2021
News, Private Securities Litigation Reform Act, Therapeutic Advances in Psychopharmacology, Forward-looking statement, Company, WVIC, Severe acute respiratory syndrome coronavirus 2, Principal investigator, Clinical trial, Human, FRA, COVID-19, CSE, Vaccination, Legislation, Technology, Research, SCOPUS, Risk, Degenerative disease, Marketing, Patent, OTCQB, ESCI, CA, PubMed, Editorial board, Pharmaceutical industry

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.

Key Points: 
  • Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.
  • It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC.
  • "We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys.
  • BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Chief Medical Officer David Berd, MD, Invited by Editorial Board of Therapeutic Advances in Vaccines and Immunotherapy to Submit a Review Article on Haptenized Protein Vaccine Platform

Retrieved on: 
Thursday, November 18, 2021
News, Private Securities Litigation Reform Act, Therapeutic Advances in Psychopharmacology, Forward-looking statement, Company, WVIC, Severe acute respiratory syndrome coronavirus 2, Principal investigator, Clinical trial, Human, FRA, COVID-19, CSE, Vaccination, Legislation, Technology, Research, SCOPUS, Risk, Degenerative disease, Marketing, Patent, OTCQB, ESCI, CA, PubMed, Editorial board, Pharmaceutical industry

Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.

Key Points: 
  • Therapeutic Advances in Vaccines and Immunotherapyis a prestigious peer-reviewed journal focused on advances in the fields of vaccinology and immunotherapy, reporting on both prophylactic and therapeutic vaccination as well as other immunotherapeutic interventions.
  • It has a strong clinical, immunological and translational focus, is PubMed, SCOPUS and ESCI-indexed, and is an official partner journal of WVIC.
  • "We are extremely pleased that Dr Berd is being commissioned to prepare a review article, especially for such a well-regarded publication," says Ken Kovan, President & Chief Operating Officer of BioVaxys.
  • BioVaxys has multiple issued U.S. patents and pending patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.